NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug [Yahoo! Finance]
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement